Article

CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors

2020-07-29

Abstract excerpt

Cancer patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi) experience various side effects, with hematological toxicity being most common. Short term treatment of mice with olaparib resulted in depletion of reticulocytes, B cell progenitors and immature thymocytes, whereas longer treatment induced broader myelosuppression. We performed a CRISPR/Cas9 screen targeting DNA repair genes to identify s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: be5faf8f-2d5f-544b-a4df-e526ee46644a
DOI: 10.1101/2020.07.28.222927

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitorsDOI 10.1101/2020.07.28.222927Read

Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivitySemantic proximity Read

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategiesSemantic proximity Read

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivitySemantic proximity Read

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer modelsSemantic proximity Read

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read

Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancerSemantic proximity Read

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human CellsSemantic proximity Read

<i>BRCA2</i> abrogation triggers innate immune responses potentiated by treatment with PARP inhibitorsSemantic proximity Read

Targeting CDK 9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian CancerSemantic proximity Read

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacySemantic proximity Read

Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer.Semantic proximity Read